Leerink Partnrs Brokers Cut Earnings Estimates for AxoGen

AxoGen, Inc. (NASDAQ:AXGN) – Equities research analysts at Leerink Partnrs reduced their FY2028 EPS estimates for AxoGen in a research note issued to investors on Tuesday, October 15th. Leerink Partnrs analyst M. Kratky now anticipates that the medical equipment provider will post earnings per share of $0.12 for the year, down from their previous estimate of $0.13. The consensus estimate for AxoGen’s current full-year earnings is ($0.33) per share.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. The company had revenue of $47.91 million during the quarter, compared to analysts’ expectations of $43.27 million. AxoGen had a negative return on equity of 17.30% and a negative net margin of 9.53%.

AXGN has been the topic of several other reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $15.00 price target on shares of AxoGen in a research report on Thursday, June 20th. Raymond James initiated coverage on AxoGen in a research note on Monday, July 1st. They issued an “outperform” rating and a $13.00 price objective for the company. StockNews.com upgraded AxoGen from a “hold” rating to a “buy” rating in a research report on Tuesday. Finally, JMP Securities upped their price target on AxoGen from $17.00 to $20.00 and gave the stock a “market outperform” rating in a research report on Friday, August 9th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $15.00.

AxoGen Price Performance

Shares of NASDAQ:AXGN opened at $13.24 on Friday. The company has a quick ratio of 2.32, a current ratio of 3.51 and a debt-to-equity ratio of 0.70. The stock has a market capitalization of $578.65 million, a PE ratio of -26.48 and a beta of 1.13. The firm’s 50 day moving average price is $13.26 and its 200-day moving average price is $9.40. AxoGen has a twelve month low of $3.45 and a twelve month high of $15.23.

Hedge Funds Weigh In On AxoGen

Several large investors have recently made changes to their positions in AXGN. nVerses Capital LLC purchased a new stake in shares of AxoGen during the third quarter worth about $56,000. Koss Olinger Consulting LLC bought a new stake in shares of AxoGen during the second quarter valued at approximately $75,000. Lazard Asset Management LLC lifted its holdings in shares of AxoGen by 30.1% in the first quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider’s stock worth $93,000 after buying an additional 2,671 shares in the last quarter. Acadian Asset Management LLC bought a new position in shares of AxoGen during the second quarter worth $125,000. Finally, BNP Paribas Financial Markets grew its stake in AxoGen by 8.6% during the first quarter. BNP Paribas Financial Markets now owns 20,820 shares of the medical equipment provider’s stock valued at $168,000 after acquiring an additional 1,651 shares in the last quarter. 80.29% of the stock is currently owned by hedge funds and other institutional investors.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.